Prognostic significance of NSE mRNA in advanced NSCLC treated with gefitinib

• Autores: Y. Wang, T. Tang, A. Sui, W. Jiao, Y. Luo, M. Wang, R. Yang, Z. Wang, Y. Shen
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 15, Nº. 5, 2013, págs. 384-390
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Purpose Current knowledge of the prognostic biomarkers of advanced non-small cell lung cancer (NSCLC) treated with gefitinib is poor. NSE mRNA as a potential prognostic biomarker of the effectiveness of gefitinib treatment in NSCLC, especially in the Chinese population, needs to be further validated.

    Patients and Methods We retrospectively reviewed 168 advanced NSCLC patients treated with gefitinib between May 2006 and July 2010. NSE mRNA was measured using quantitative RT-PCR analysis for correlation with the clinical outcomes.

    Results We found that NSE mRNA expression was inversely correlated with sensitivity to gefitinib in NSCLC patients. Patients without elevated NSE mRNA had a more RR (CR + RR) 45.1 % than elevated 18.9 % (P = 0.0005). Moreover, the time to progression was 6.0 versus 4.2 months, respectively. Log-rank test was marginally significant (?2 = 12.11, P = 0.0007) and Cox multivariate analysis revealed that NSE mRNA (HR = 3.076; 95 % CI 1.943�4.870; P < 0.0001) was an independent prognostic factor of NSCLC patients in the Chinese population.

    Conclusion For NSCLC patients treated with gefitinib, patients without elevated NSE mRNA had a better prognosis than those with elevated NSE mRNA. Pretreatment NSE mRNA holds great potential as a prognostic biomarker in advanced NSCLC. Therefore, it is proposed that NSE mRNA should be routinely detected to screen patients who are more likely to benefit from gefitinib-based treatment.